A fund-raising drive is ongoing to finance a randomized, double-blind, placebo-controlled trial (RCT) to determine the safety and dose-dependent efficacy of high-dose thiamine (B1) in Parkinson’s Disease.
RCTs are currently considered the gold standard in research in the medical field.
The RCT will provide the evidence on the effectiveness of the HDT (B1) therapy protocol that the international health community is waiting for, to make it acceptable to the scientific community and available to the millions of People with Parkinson’s Disease.
More information on the methodology and other details on the RCT is available in the
Research pages of this website.